Seroquel, which generated sales of $4.9 billion last year, is AstraZeneca's second-biggest seller after the ulcer treatment Nexium. “The evidence, looked at ...
... the company come to an accommodation with Israel-based rival Teva Pharmaceuticals over the latter's generic version of Astra's Nexium ulcer capsules, ...
